Irifune Masahiro, Kikuchi Nobuhito, Saida Takuya, Takarada Tohru, Shimizu Yoshitaka, Endo Chie, Morita Katsuya, Dohi Toshihiro, Sato Tomoaki, Kawahara Michio
Department of Dental Anesthesiology, Division of Clinical Medical Science, Programs for Applied Biomedicine, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
Anesth Analg. 2007 Jun;104(6):1415-21, table of contents. doi: 10.1213/01.ane.0000263267.04198.36.
The general anesthetic state comprises behavioral and perceptual components, including amnesia, unconsciousness, analgesia, and immobility. In vitro, glutamatergic excitatory neurons are important targets for anesthetic action at the cellular and microcircuits levels. Riluzole (2-amino-6-[trifluoromethoxy]benzothiazole) is a neuroprotective drug that inhibits glutamate release from nerve terminals in the central nervous system. Here, we examined in vivo the ability of riluzole to produce components of the general anesthetic state through a selective blockade of glutamatergic neurotransmission.
Riluzole was administered intraperitoneally in adult male ddY mice. To assess the general anesthetic components, three end-points were used: 1) loss of righting reflex (LORR; as a measure of unconsciousness), 2) loss of movement in response to noxious stimulation (as a measure of immobility), and 3) loss of nociceptive response (as a measure of analgesia).
The intraperitoneal administration of riluzole induced LORR in a dose-dependent fashion with a 50% effective dose value of 27.4 (23.3-32.2; 95% confidence limits) mg/kg. The behavioral and microdialysis studies revealed that time-course changes in impairment and LORR induced by riluzole corresponded with decreased glutamate levels in the mouse brain. This suggests that riluzole-induced LORR (unconsciousness) could result, at least in part, from its ability to decrease brain glutamate concentrations. Riluzole dose-dependently produced not only LORR, but also loss of movement in response to painful stimulation (immobility), and loss of nociceptive response (analgesia) with 50% effective dose values of 43.0 (37.1-49.9), and 10.0 (7.4-13.5) mg/kg, respectively. These three dose-response curves were parallel, suggesting that the behavioral effects of riluzole may be mediated through a common site of action.
These findings suggest that riluzole-induced LORR, immobility, and antinociception appear to be associated with its ability to inhibit glutamatergic neurotransmission in the central nervous system.
全身麻醉状态包括行为和感知成分,包括失忆、无意识、镇痛和不动。在体外,谷氨酸能兴奋性神经元是细胞和微回路水平上麻醉作用的重要靶点。利鲁唑(2-氨基-6-[三氟甲氧基]苯并噻唑)是一种神经保护药物,可抑制中枢神经系统神经末梢释放谷氨酸。在此,我们在体内研究了利鲁唑通过选择性阻断谷氨酸能神经传递产生全身麻醉状态成分的能力。
对成年雄性ddY小鼠腹腔注射利鲁唑。为评估全身麻醉成分,使用了三个终点指标:1)翻正反射消失(LORR;作为无意识的指标),2)对有害刺激无运动反应(作为不动的指标),3)伤害性反应消失(作为镇痛的指标)。
腹腔注射利鲁唑以剂量依赖性方式诱导LORR,半数有效剂量值为27.4(23.3 - 32.2;95%置信区间)mg/kg。行为和微透析研究表明,利鲁唑诱导的功能损害和LORR的时间进程变化与小鼠脑内谷氨酸水平降低相对应。这表明利鲁唑诱导的LORR(无意识)至少部分可能是由于其降低脑谷氨酸浓度的能力。利鲁唑不仅剂量依赖性地产生LORR,还产生对疼痛刺激无运动反应(不动)和伤害性反应消失(镇痛),半数有效剂量值分别为43.0(37.1 - 49.9)和10.0(7.4 - 13.5)mg/kg。这三条剂量 - 反应曲线平行,表明利鲁唑的行为效应可能通过共同的作用位点介导。
这些发现表明,利鲁唑诱导的LORR、不动和抗伤害感受似乎与其抑制中枢神经系统谷氨酸能神经传递的能力有关。